151 related articles for article (PubMed ID: 37742327)
1. Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis.
Sultan MI; Huynh LM; Kamil S; Abdelaziz A; Hammad MA; Gin GE; Lee DI; Youssef RF
Int Urol Nephrol; 2024 Feb; 56(2):539-546. PubMed ID: 37742327
[TBL] [Abstract][Full Text] [Related]
2. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies.
Margolis E; Brown G; Partin A; Carter B; McKiernan J; Tutrone R; Torkler P; Fischer C; Tadigotla V; Noerholm M; Donovan MJ; Skog J
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):296-301. PubMed ID: 34593984
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
4. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
[TBL] [Abstract][Full Text] [Related]
5. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL.
Tutrone R; Donovan MJ; Torkler P; Tadigotla V; McLain T; Noerholm M; Skog J; McKiernan J
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):607-614. PubMed ID: 32382078
[TBL] [Abstract][Full Text] [Related]
7. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
10. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.
Tutrone R; Lowentritt B; Neuman B; Donovan MJ; Hallmark E; Cole TJ; Yao Y; Biesecker C; Kumar S; Verma V; Sant GR; Alter J; Skog J
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):596-601. PubMed ID: 37193776
[TBL] [Abstract][Full Text] [Related]
11. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
Bhat NR; Vetter JM; Andriole GL; Shetty AS; Ippolito JE; Kim EH
Urology; 2019 Apr; 126():152-157. PubMed ID: 30580005
[TBL] [Abstract][Full Text] [Related]
12. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
Bretton PR; Evans WP; Borden JD; Castellanos RD
Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
[TBL] [Abstract][Full Text] [Related]
13. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
14. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
Kretschmer A; Tutrone R; Alter J; Berg E; Fischer C; Kumar S; Torkler P; Tadigotla V; Donovan M; Sant G; Skog J; Noerholm M
World J Urol; 2022 Apr; 40(4):983-989. PubMed ID: 35084544
[TBL] [Abstract][Full Text] [Related]
15. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
Dwivedi DK; Kumar R; Dwivedi AK; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
[TBL] [Abstract][Full Text] [Related]
16. Low AUA symptom score independently predicts positive prostate needle biopsy: results from a racially diverse series of 411 patients.
Porter CR; Kim J
Urology; 2004 Jan; 63(1):90-4. PubMed ID: 14751356
[TBL] [Abstract][Full Text] [Related]
17. How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.
Moul JW; Sant GR
Can J Urol; 2022 Aug; 29(4):11224-11230. PubMed ID: 35969726
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
[TBL] [Abstract][Full Text] [Related]
19. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
20. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
